Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Alt text (EN) This picture shows several doctors looking at a medical image within the program mint Lesion™

On-Site BZKF BORN Roll-Out Trainings Keep on Going

Our expert Steffen Rupp recently visited the Technical University of Munich to continue the on-site BZKF BORN Roll-Out Trainings. As mentioned…

This image shows a scan of pericardial effusion

Unveiling the Predictive Power of Pericardial Effusion in COVID-19 Outcomes

The COVID-19 pandemic wreaked havoc on healthcare systems worldwide, requiring a comprehensive understanding of disease progression for optimal…

Image shows two open hands holding a gray cancer ribbon in their palms

Advancing Childhood Cancer Research: The Role of Technology in Brain Tumor Diagnosis and Treatment

Brain cancers account for more than 15% of childhood cancers and are the second most common childhood cancer [1]. Mint Medical is Going Gray in May…